Literature DB >> 22447519

FGF23 and PTH--double agents at the heart of CKD.

Justin Silver1, Mariano Rodriguez, Eduardo Slatopolsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22447519      PMCID： PMC3471546          DOI： 10.1093/ndt/gfs050

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  58 in total

1.  Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule.

Authors:  Ming Chang Hu; Mingjun Shi; Jianning Zhang; Johanne Pastor; Teruyo Nakatani; Beate Lanske; M Shawkat Razzaque; Kevin P Rosenblatt; Michel G Baum; Makoto Kuro-o; Orson W Moe
Journal:  FASEB J       Date:  2010-05-13       Impact factor: 5.191

2.  FGF23 fails to inhibit uremic parathyroid glands.

Authors:  Rocío Canalejo; Antonio Canalejo; Julio Manuel Martinez-Moreno; M Encarnacion Rodriguez-Ortiz; Jose C Estepa; Francisco Javier Mendoza; Juan Rafael Munoz-Castaneda; Victoria Shalhoub; Yolanda Almaden; Mariano Rodriguez
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

3.  PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.

Authors:  Vardit Lavi-Moshayoff; Gilad Wasserman; Tomer Meir; Justin Silver; Tally Naveh-Many
Journal:  Am J Physiol Renal Physiol       Date:  2010-08-04

4.  Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity.

Authors:  Tetsuro Kusaba; Mitsuhiko Okigaki; Akihiro Matui; Manabu Murakami; Kazuhiko Ishikawa; Taikou Kimura; Kazuhiro Sonomura; Yasushi Adachi; Masabumi Shibuya; Takeshi Shirayama; Shuji Tanda; Tsuguru Hatta; Susumu Sasaki; Yasukiyo Mori; Hiroaki Matsubara
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-21       Impact factor: 11.205

5.  The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel.

Authors:  Q Chang; S Hoefs; A W van der Kemp; C N Topala; R J Bindels; J G Hoenderop
Journal:  Science       Date:  2005-10-21       Impact factor: 47.728

6.  Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease.

Authors:  H Galitzer; I Z Ben-Dov; Justin Silver; Tally Naveh-Many
Journal:  Kidney Int       Date:  2009-12-16       Impact factor: 10.612

Review 7.  Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

8.  Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.

Authors:  Liping Xiao; Takahiro Naganawa; Joseph Lorenzo; Thomas O Carpenter; J Douglas Coffin; Marja M Hurley
Journal:  J Biol Chem       Date:  2009-11-20       Impact factor: 5.157

9.  Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients.

Authors:  Hirotaka Komaba; Shunsuke Goto; Hideki Fujii; Yasuhiro Hamada; Akira Kobayashi; Koji Shibuya; Yoshihiro Tominaga; Naoki Otsuki; Ken-Ichi Nibu; Kimie Nakagawa; Naoko Tsugawa; Toshio Okano; Riko Kitazawa; Masafumi Fukagawa; Tomoyuki Kita
Journal:  Kidney Int       Date:  2009-11-04       Impact factor: 10.612

10.  Novel regulators of Fgf23 expression and mineralization in Hyp bone.

Authors:  Shiguang Liu; Wen Tang; Jianwen Fang; Jinyu Ren; Hua Li; Zhousheng Xiao; L D Quarles
Journal:  Mol Endocrinol       Date:  2009-06-25
View more
  24 in total

Review 1.  Diagnosis and Management of Heart Failure in Long-Term Dialysis Patients.

Authors:  Ashraf S Abdo
Journal:  Curr Heart Fail Rep       Date:  2017-10

2.  Zinc-α2-Glycoprotein Exerts Antifibrotic Effects in Kidney and Heart.

Authors:  Inga Sörensen-Zender; Sagar Bhayana; Nathan Susnik; Veronique Rolli; Sandor Batkai; Arpita Baisantry; Siamak Bahram; Payel Sen; Beina Teng; Robert Lindner; Mario Schiffer; Thomas Thum; Anette Melk; Hermann Haller; Roland Schmitt
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

Review 3.  The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder.

Authors:  Michael E Seifert; Keith A Hruska
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

4.  The induction of C/EBPβ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.

Authors:  Maria Vittoria Arcidiacono; Jing Yang; Elvira Fernandez; Adriana Dusso
Journal:  Nephrol Dial Transplant       Date:  2014-10-07       Impact factor: 5.992

Review 5.  The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.

Authors:  Keith A Hruska; Toshifumi Sugatani; Olga Agapova; Yifu Fang
Journal:  Bone       Date:  2017-01-22       Impact factor: 4.398

6.  Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice.

Authors:  Maria Vittoria Arcidiacono; Jing Yang; Elvira Fernandez; Adriana Dusso
Journal:  Nephrol Dial Transplant       Date:  2014-10-16       Impact factor: 5.992

7.  Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enema.

Authors:  Carolina Gracia-Iguacel; Emilio Gonzalez-Parra; Laura Rodriguez-Osorio; Ana Belén Sanz; Yolanda Almaden; Concepcion de la Piedra; Jesus Egido; Mariano Rodriguez; Alberto Ortiz
Journal:  J Bone Miner Metab       Date:  2013-05-16       Impact factor: 2.626

Review 8.  αKlotho and Chronic Kidney Disease.

Authors:  J A Neyra; M C Hu
Journal:  Vitam Horm       Date:  2016-03-24       Impact factor: 3.421

Review 9.  FGF-23 and secondary hyperparathyroidism in chronic kidney disease.

Authors:  Justin Silver; Tally Naveh-Many
Journal:  Nat Rev Nephrol       Date:  2013-07-23       Impact factor: 28.314

Review 10.  Pathophysiology of the chronic kidney disease-mineral bone disorder.

Authors:  Keith A Hruska; Michael Seifert; Toshifumi Sugatani
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-07       Impact factor: 2.894
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.